The osteogenic effects of activin A have been shown in both in vitro and in vivo studies as reviewed by Sakai and Eto (8) . First, the cytokine was found to be produced by osteoblasts and released into bone matrix in the process of fracture healing in rats. In subsequent experiments, local injection of activin A stimulated callus formation and improved mechanical strength of the fractured bone. In a further study, Sakai and coworkers found that intramuscular injections of activin A not only prevented bone loss in aged ovariectomized rats but even increased the mineral content and density in such osteoporosis-prone lumbar vertebrae (9) . These studies imply that activin A is strongly involved in the process of osteoporosis, and may be effective in its treatment.
Patients with end-stage renal failure undergoing maintenance hemodialysis (HD) therapy present with an exceptional spectrum of bone diseases, including severe osteoporosis. This issue and the possible causative role of heparin used for blood anticoagulation during HD procedures in the development of osteoporosis (via up-regulated hepatocyte growth factor) have been partially addressed in our recent communication in this journal (10) . Inspired by the clinical report (11) showing that heparin also strongly stimulates the release of activin A and follistatin likely due to their displacement from cell-surface heparan sulphate glycosaminoglycans, we recently conducted a similar study in HD patients (12) . We found a striking several-fold increase in plasma activin A and follistatin levels during three times a week HD procedures using a bolus of low-molecular-weight heparin (LMWH) enoxaparin. The increases of activin A at 10 minutes and 180 minutes of HD correlated strongly and, interestingly, inversely with its pre-dialysis values. The early increase in follistatin depended directly on the dose of enoxaparin. Moreover, the pre-dialysis plasma concentration of activin A was normal, while that of its natural inhibitor-follistatin-was 2.5-fold higher than that in healthy controls. From a pharmacokinetic point of view, the above over-dialytic behavior of activin A along with its normal pre-dialysis level (despite stimulation) indicates the depletion of heparin-releasable tissue store of this pluripotent cytokine in maintenance HD patients as a result of its repeated release. The validity of this specific pharmacokinetic pattern was proven recently for tissue factor pathway inhibitor which, similarly to activin A, remains assembled with tissue proteoglycans-repeated injections of LMWH lead to exhaustion of this coagulation inhibitor in both healthy subjects (13) and HD patients (14) .
Depletion of activin A and up-regulation of its antagonist follistatin due to repeated heparin administration may have a harmful effect on bone metabolism in maintenance HD patients. The disturbances of activin A/follistatin system are also likely to be involved in the development of bone disease in other patients undergoing prolonged heparin therapy. We believe that this new pathogenetic aspect of heparin-induced osteoporosis deserves further studies. 
